Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
暂无分享,去创建一个
M. Berger | V. Reuter | I. Ostrovnaya | J. Coleman | G. Iyer | H. Al-Ahmadie | B. Bochner | D. Bajorin | D. Solit | M. Arcila | J. Rosenberg | G. Jayakumaran | G. Dalbagni | F. Audenet | E. Pietzak | E. Drill | E. Cha | T. Donahue | S. Isharwal
[1] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[2] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[3] James C. Costello,et al. TERT promoter mutations and telomerase reactivation in urothelial cancer , 2015, Science.
[4] J. Becker,et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma , 2014, Nature Communications.
[5] Z. Cai,et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. , 2014, European urology.
[6] T. Ørntoft,et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.
[7] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[8] The Cancer Genome Atlas Research Network,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[9] C. Sander,et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[11] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.